Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: Preclinical basis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4 SUPPL. 2, 2003, Pages

  Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

COX 2 inhibitors; Human cancers; Tumor radioresponse

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; ILOPROST; INDOMETACIN; MISOPROSTOL; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INHIBITION; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HYPOXIA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRECANCER; PROSTAGLANDIN SYNTHESIS; RADIATION DOSE; RADIOSENSITIVITY; TUMOR CELL DESTRUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS;

EID: 0041573047     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308002-00006     Document Type: Conference Paper

References (14)

1. Koki A, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opinion Investig Drugs 1999;8:1623-38.
2. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89:2637-45.
3. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001; 11:290-9.
4. Milas L, Hanson WR. Eicosanoids and radiation. Eur J Cancer 1995;31A:1580-5.
5. Hanson W. Eicosanoid-induced radioprotection and chemoprotection: Laboratory Studies and Clinical Applications. In: Bump E, Malaker K, eds. Radioprotectors: chemical, biological, and clinical perspectives. Boca Raton: CRC Press, 1998:197-221.
6. Furuta Y, Hunter N, Barkley T, et al. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 1988; 48:3008-13.
7. Teicher B, Bump EA, Palayoor ST, et al. Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts. Radiat Oncol Invest 1996;4:221-30.
8. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
9. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
10. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999;91:1501-4.
11. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-31.
12. Petersen C, Petersen S, Milas L, et al. Human glioma cell radiosensitization by a selective COX-2 inhibitor. Clin Cancer Res 2000;6:2513-20.
13. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
14. Milas L, Furuta Y, Hunter N, et al. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res 1990;50:4473-7.